FDA OKs Humira copycat from Merck, Samsung Bioepis — but they will wait 4 years to launch
Merck and Samsung Bioepis clinched the FDA’s endorsement of their Humira biosimilar, Hadlima, adding a key market to the list of countries where they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
